Delivery Order SPE2DB22D1017-SPE2DB25FG8NR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,356.18 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 90 units of the pharmaceutical product Valsartan-HCTZ 320-25 mg tablets. The contract has a completion date of February 5, 2024 and a potential value of $1,295.24. AmerisourceBergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation or larger contract...
- The Defense Logistics Agency awarded a $2,607.52 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count). This competitive delivery order represents a firm fixed-price transaction with an ultimate completion date of July 28, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90 units, with a ceiling value of $2,484.03. This is a firm fixed price delivery order with no set-aside designation, issued as a competitive award. The place of performance is AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. This...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,531.89 firm-fixed-price contract is for the supply of Valsartan-HCTZ 160-12.5 mg tablets, with a performance period through January 2, 2025. The contract is not designated under any set-aside program. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,943,211 units of Valsartan-HCTZ 320-12.5 mg tablets in packages of 90. The contract has a ceiling value of $10,255.95 and a period of performance through March 13, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with DLA valued at up to $999,999,999...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Valsartan-HCTZ 160-12.5 mg tablets. The contract is a firm fixed-price delivery order with a ceiling value of $6,087.44 and a period of performance through April 2025. The contract is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Valsartan-HCTZ 320-25 mg tablets. The contract has a ceiling value of $1,211.54 and is a firm fixed-price delivery order without a set-aside designation. The period of performance for this order extends to July 25, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This is a $3,615.46 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Valsartan-HCTZ 160-12.5 mg tablets in 90-count packages. The contract has an ultimate completion date of March 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Valsartan-HCTZ 320-25 mg tablets. The $2,027.97 contract has an ultimate completion date of July 9, 2025 and is not set aside. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a wide range of pharmaceutical products and medical supplies in...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8NRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count units) with a ceiling value of $2,651.15. This delivery order, issued under firm fixed-price terms with no set-aside designation, represents a competitively awarded procurement from AmerisourceBergen's existing indefinite delivery contract vehicle with the DLA. The product will be performed at the company's Conshohocken, Pennsylvania location and is scheduled for completion by July 31, 2025. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's $999,999,999.00 Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor within the federal medical supply chain, providing a comprehensive range of medications and medical supplies to support military healthcare systems, the Defense Health Agency, and other government customers. The company's federal procurement portfolio demonstrates consistent performance in delivering diverse pharmaceutical products across multiple therapeutic domains, positioning it as a key vendor for the Department of Defense medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 7/30/25 |